Investigation of Docosahexaenoic Acid (DHA) Metabolic Pathway in Human by Using 13C Labeled Molecules
AceDoPC
Bioavailability of DHA-TG (Docosahexaenoic Triglyceride), DHA-PC (Docosahexaenoic Phosphatidylcholine) and AcedoPC (1-acetyl-2-docosahexaenoic-glycerophosphocholine) in Human
1 other identifier
interventional
4
1 country
1
Brief Summary
The purpose of this study is to compare three lipidic forms of DHA in their metabolic pathway in human by using 13C labeled molecules. The circulating form of DHA plays a major role in his cerebral incorporation. The aim of this research is to confirm that some lipidic forms are best carriers for the cerebral incorporation in studying 13C-DHA distribution in plasma lipids and blood cells.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2014
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2014
CompletedFirst Submitted
Initial submission to the registry
March 21, 2014
CompletedFirst Posted
Study publicly available on registry
June 20, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2015
CompletedDecember 19, 2025
December 1, 2025
1.1 years
March 21, 2014
December 13, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Concentration of 13C-DHA in red blood cells
6 hours after product ingestion
At Day 1
Secondary Outcomes (2)
Concentration of 13C-DHA in plasma lipids
At Day 1
Concentration of 13C-DHA in platelets
At Day 1
Study Arms (3)
13-C labeled PC-DHA
ACTIVE COMPARATOR13-C labeled TG-DHA
ACTIVE COMPARATOR13-C labeled AceDoPC-DHA
EXPERIMENTALInterventions
Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C. The dose contains 50 mg 13C-DHA. The wash-out period is four months
Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C. The dose contains 50 mg 13C-DHA. The wash-out period is four months
Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C. The dose contains 50 mg 13C-DHA. The wash-out period is four months
Eligibility Criteria
You may qualify if:
- Healthy male
- Aged of 60 to 70 years
- Body Mass Index of 20 to 30 kg/m2
- Glycaemic and lipid parameters normal
You may not qualify if:
- Smokers more than ten cigarettes/day
- Medical history of personal or family dyslipidemia
- Medication that could interfere with lipid metabolism
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre de Recherche en Nutrition Humaine Rhône-Alpes, 165 chemin du Grand Revoyet,
Pierre-Bénite, 69310, France
Related Publications (1)
Hachem M, Nacir H, Picq M, Belkouch M, Bernoud-Hubac N, Windust A, Meiller L, Sauvinet V, Feugier N, Lambert-Porcheron S, Laville M, Lagarde M. Docosahexaenoic Acid (DHA) Bioavailability in Humans after Oral Intake of DHA-Containing Triacylglycerol or the Structured Phospholipid AceDoPC(R). Nutrients. 2020 Jan 18;12(1):251. doi: 10.3390/nu12010251.
PMID: 31963708RESULT
Related Links
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 21, 2014
First Posted
June 20, 2014
Study Start
March 1, 2014
Primary Completion
April 1, 2015
Study Completion
April 1, 2015
Last Updated
December 19, 2025
Record last verified: 2025-12